Sage, Biogen get rolling on FDA submission for depression med

Sage Therapeutics and Biogen’s zuranolone is heading off to the FDA for consideration in treating major depressive disorder (MDD) as a two-week, once-daily drug to bridge the time it takes for traditional therapies to kick in.